Focus and Scope

1. Clinical and Translational Medicine

The evidentiary core of the journal. Track I receives original clinical investigation across the breadth of internal medicine, surgery, obstetrics and gynaecology, paediatrics, emergency and critical care medicine, oncology, cardiology, endocrinology and metabolic disease, infectious disease, neurology, psychiatry, geriatrics, and the diagnostic specialties: interventional trials and their pragmatic variants; prospective and retrospective cohort studies of sufficient size and follow-up to speak to hard endpoints; diagnostic and prognostic model development and external validation; comparative effectiveness research; and systematic reviews and meta-analyses that resolve uncertainty rather than restate it. The track is equally the journal's translational corridor, welcoming first-in-human and early-phase work, biomarker qualification, and mechanistic investigation where a plausible line of sight to a patient endpoint can be articulated; bench science pursued for its own sake falls outside the track, the boundary being not the sophistication of the method but the identifiability of the patient at the far end of it. Authors of interventional and diagnostic studies are strongly encouraged to append an implementation statement addressing the staffing, cost, supply, training, and workflow conditions under which the finding would reproduce in an institution unlike their own.

2. Health Systems, Leadership, and the Quality of Care

? If Track I establishes what should be done, Track II establishes why it so frequently is not — the journal's distinctive contribution and the direct expression of its philosophy, treating the organisation of care as an object of clinical science subject to the same demands of measurement, control, replication, and outcome reporting as any pharmacological intervention. The track receives quality-improvement science reported to SQUIRE 2.0; patient-safety research spanning incident reporting, root-cause and systems analysis, human-factors investigation, diagnostic error, medication error, and the epidemiology of preventable harm; studies of clinical governance, credentialling, and accountability structure; investigations of clinical leadership, team function, psychological safety, and the measurable relationship between organisational culture and mortality, readmission, infection, and length of stay; workforce science examined against a clinical endpoint rather than a satisfaction score alone; health-service financing, payment design, and clinician behaviour under incentive; accreditation and regulatory science; digital health and the informatics of delivery; and enterprise risk management as applied to the hospital — the identification, quantification, mitigation, and governance of the exposures that determine whether an institution can keep the promises its clinicians make.

3. Clinical Pharmacy, Pharmacotherapy, and Pharmacoeconomics

The pharmacological intention is the point at which clinical medicine most frequently and most consequentially meets the system, and this track is dedicated to the whole of that meeting. It receives applied pharmacotherapy research — comparative effectiveness and safety of drug regimens, therapeutic drug monitoring and dose individualisation, pharmacokinetic and pharmacodynamic investigation with a clinical endpoint, drug interaction studies, deprescribing and polypharmacy, adherence science, and pharmacovigilance; the clinical-pharmacy services literature — the measurable effect of pharmacist integration into ward rounds, discharge reconciliation, and multidisciplinary teams, antimicrobial and analgesic stewardship, and physician–pharmacist collaborative care models; and the economic and managerial layer without which the preceding two are inert — formulary design and evidence-based medicine committee methodology, cost-effectiveness and budget-impact analysis reported to CHEERS 2022, health technology assessment, pharmaceutical supply-chain integrity, and procurement and pricing policy.

4. Public Health, Oral Health, and Community Nutrition

The hospital is a late and expensive point of contact with a disease process that began, in most cases, years earlier and elsewhere. This track extends the journal's outcome discipline upstream of admission. It receives epidemiological investigation of communicable and non-communicable disease; health-policy analysis evaluated against measured population outcomes; health-systems strengthening and primary-care research; immunisation science and coverage; maternal, child, and adolescent health; health-equity research; and health-promotion interventions evaluated against a defensible counterfactual. Oral health is admitted as a full clinical constituent — dental public health, oral epidemiology, oral–systemic disease research, and preventive oral health policy — on the strength of the evidentiary link between periodontal disease and cardiovascular, diabetic, and adverse pregnancy outcomes. Clinical and community nutrition is admitted on identical grounds, receiving inpatient clinical nutrition and dietetics, nutritional screening and support protocols and their outcomes, malnutrition and micronutrient deficiency, and community nutrition intervention.

5. Medical Economics, Risk Governance, and the Value of Care

Resources are finite; the allocation of them is therefore an act with a mortality signature, whether or not it is performed by a clinician, and whether or not anyone measures it. This track insists that it be measured. It receives health economics applied to the clinical decision and the clinical institution — costing methodology, value-based care design and evaluation, outcome measurement, payment and reimbursement architecture, insurance and coverage design, and capacity planning; enterprise and clinical risk governance — risk identification and quantification in the healthcare setting, medico-legal exposure, business continuity and disaster preparedness, pandemic and surge planning, and institutional decision-making under uncertainty; and the sociology and political economy of the medical institution — how professional hierarchy, organisational structure, and financing arrangement act upon clinical behaviour, and thereby upon the patient.

Scope Boundary Statement. This journal is, without qualification, a clinical journal. Its breadth is a claim about the causes of patient outcomes, not a relaxation of the standard by which manuscripts are judged, and it is enforced as strictly at the periphery of the scope as at its centre. Every manuscript accepted by this journal, in every track, must terminate in a patient. The editorial board applies a single, non-negotiable test at first screening: can the authors identify the clinical outcome — realised, plausibly proximate, or explicitly modelled — that their work bears upon, and have they measured or defensibly estimated it? A study of hospital leadership reporting only staff attitudes; a health-economic analysis reporting only cost without effect; a nutrition survey reporting only intake without status or outcome; a policy paper reporting only policy; a management study reporting only process compliance without the harm the process was instituted to prevent — each is declined without external review. The line this journal draws is not between medicine and management. It is between work that reaches the patient and work that stops short of it. The journal does not publish: management, organisational, economic, or leadership research conducted outside the healthcare setting or without a healthcare outcome; business, marketing, or human-resources scholarship for which the hospital is merely a convenient sample; basic laboratory science without an articulated translational pathway; educational research without a demonstrated or credibly modelled effect on clinical competence or patient outcome; commentary unsupported by evidence; and manuscripts in any discipline whose relationship to health is asserted rather than demonstrated. Submission to Track II, III, IV, or V is not an easier route to publication than submission to Track I; it is a different route to the same endpoint, subject to the same reporting standards, statistical scrutiny, pre-registration requirements, conflict-of-interest disclosure, and clinical adjudication. A health-systems manuscript is, in this journal's terms, a clinical manuscript with a longer causal chain — refereed with more scrutiny of that chain, not less